(Q35965038)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Maher K Gandhi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 December 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

725-738

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

ULTRASTRUCTURAL, CYTOCHEMICAL, AND MICROCHEMICAL OBSERVATIONS ON CYTOMEGALOVIRUS (SALIVARY GLAND VIRUS) INFECTION OF HUMAN CELLS IN TISSUE CULTURE.

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Epidemiology and transmission of cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytomegalovirus Infection in Sexually Active Adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Congenital cytomegalovirus infection: epidemiology and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Congenital cytomegalovirus infection: review of the epidemiology and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Occult herpes family viruses may increase mortality in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

The economic impact of cytomegalovirus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

An association between cytomegalovirus infection and chronic rejection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Coronary artery disease after heart transplantation and its relation to cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Strategies for the prevention of cytomegalovirus disease after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Practical protocol for cytomegalovirus isolation: use of MRC-5 cell monolayers incubated for 2 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Prenatal diagnosis of congenital human cytomegalovirus infection in amniotic fluid by nucleic acid sequence-based amplification assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Anticytomegalovirus IgG avidity in pregnancy: a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Vital involvement of a natural killer cell activation receptor in resistance to viral infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Severe herpesvirus infections in an adolescent without natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Viral mechanisms of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Viral mimicry of cytokines, chemokines and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Recombinant cytomegaloviruses for study of replication and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Optimization of DNA immunization against human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

The immunogenicity of human and murine cytomegaloviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901202-2

7 January 2021

10.1016/S1473-3099(04)01202-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15567122%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference